CA 27.29

CA 27.29

abbreviation for cancer antigen CA 27.29, a blood tumor marker used for staging breast cancer and monitoring its treatment.
References in periodicals archive ?
3) These patients were also evaluated for other prognostic cancer markers, such as hormone receptor status, CA 27.
CTC assays may offer higher predictive value than many commonly utilized tests such as measurements of hormone receptor status, CA 27.
MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 153, CA 27.
20] summarized the utility of serum tumor markers in highest usage; the analytes included [alpha]-fetoprotein (AFP), CA 125, CA 15-3, CA 27.
of individual Analyte tested tests/laboratories ACTH (a) 2 10/2 ACTOn Ab 1 9/1 ACTPO 1 9/1 AFP 12 105/18 Anti-HAV 1 2/1 Anti-HCV 1 2/1 Anti-TG Ab 3 19/3 Anti-TPO Ab 2 27/3 ATPOn Ab 1 9/1 [R]-hCG + hCG 15 281/40 CA 125 12 124/19 CA 15-3 10 97/14 CA 19-9 10 84/10 CA 27.
The diagnostic sensitivities included: CA 50 (70%), CA 19-9 (64%), CA 195 (58%), CEA (50%), CA15-3 (45%), CA 125 (40%), CA 27.
Keywords: cancer, gastric cancer, stomach cancer, carcinoembryonic antigen, alpha-fetoprotein, CEA, AFP, CA 50, CA 19-9, CA 195, CA 72-4, CA 125, CA 15-3, CA 27.
This result is two times more sensitive than the current cancer monitoring blood tests CA 27.
These include [alpha]-fetoprotein (AFP), CA 125, CA 15-3, CA 27.
It is interesting to note that, while the number of CA 27.
Keywords: cancer, breast cancer, carcinoembryonic antigen, alpha-fetoprotein, CEA, AFP, CA 15-3, CA 27.
Edmonton, Alberta, Canada) for the quantitativn of serum CA 27.